Cardiac DiseasesHerzerkrankungen
    Home
    t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.

    Cardiac Diseases

    t2cure’s focus is on developing regenerative medicine therapeutics to treat cardiac diseases. Specifically, acute myocardial infarction and chronic ischemic heart disease will be targeted by t2cure’s product candidates.

    Today’s standard therapies for acute myocardial infarction are acute reperfusion and stenting of the respective coronary artery as well as anti-thrombotic therapies. These therapies cannot avoid the later sequelae of the disease, namely ventricular remodelling. Since the human heart only has very limited ability to regenerate itself it can normally not compensate for the consequences of an acute myocardial infarction, namely tissue damage in the affected region of the heart and massive cell death due to oxygen deprivation. For both, acute myocardial infarction and chronic ischemic heart diseases, this leads to an increased morbidity and mortality for patients. The goal is to increase cardiac regeneration on top of standard therapies, to improve ventricular function and to increase the number of viable and functional cells in the diseased cardiac tissue, thereby ameliorating the effects of cardiac remodelling with the long term goal of reducing morbidity and mortality of patients with large myocardial infarctions and depressed left ventricular contractile function.